North American Juvenile Myelomonocytic Leukemia Project
北美幼年粒单核细胞白血病项目
基本信息
- 批准号:7263969
- 负责人:
- 金额:$ 2.86万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2003
- 资助国家:美国
- 起止时间:2003-07-03 至 2007-06-30
- 项目状态:已结题
- 来源:
- 关键词:AddressAdolescentAmericanBasic ScienceBiochemicalBiologicalCancer Therapy Evaluation ProgramCellsChildren&aposs Oncology GroupClinicalClinical TrialsDataDiseaseDrug resistanceFarnesyl Transferase InhibitorFrequenciesFutureGene AbnormalityGoalsGranulocyte-Macrophage Colony-Stimulating FactorGrowth FactorHRAS geneHumanHypersensitivityIn VitroInternetInvestigationInvestigational TherapiesIsotretinoinJuvenile Myelomonocytic LeukemiaLaboratory StudyLinkMalignant NeoplasmsModalityMyeloproliferative diseaseNF1 genePathogenesisPathway interactionsPatientsPharmacodynamicsPhasePhase III Clinical TrialsPrognostic MarkerProtein FarnesylationProtocols documentationRangeResearch PersonnelResourcesRestSamplingSignal TransductionSiteStem cell transplantSupervisionSystemTailTestingTherapeuticTissue BanksToxic effectTransferaseTreatment Protocolsbasecell registrychemotherapydesignefficacy evaluationimprovedin vivoinhibitor/antagonistleukemiamouse modelnovelresearch studyresponsetherapeutic targettranslational study
项目摘要
DESCRIPTION (provided by applicant): The pathogenesis of JMML has been linked to dysregulated GM-CSF growth factor signal transduction through the Ras pathway, with abnormalities identified in the RAS and NF1 genes in this pathway. This dysregulation results in JMML cells demonstrating selective hypersensitivity to GM-CSF in vitro. One of the new treatment modalities in JMML, 13-cis retinoic acid therapy, appears to modulate this GM-CSF hypersensitivity. A new multi-modality treatment protocol for JMML has recently been approved by the CTEP branch of the NCI. This protocol will be administered through the Children's Oncology Group and is a phase II window/phase III trial. Experimental therapy with a farnesyl transferase inhibitor will be tested in the phase II window, followed by 13-cis retinoic acid, chemotherapy, and stem cell transplantation in the phase III portion. One of the many advantages of this type of trial design is that it permits the rigorous evaluation of the efficacy of a single agent in untreated JMML patients who have not developed drug resistance. If one phase II agent tails, the protocol is designed to allow for the substitution of a different agent without disrupting the rest of the study. Three experimental agents can be nearly fully tested during the course of the phase III trial. Laboratory studies will evaluate whether they are truly acting as mechanism-based therapeutics. The principal aims of this application are to utilize the patient resources from this protocol as a conduit for accruing cases to address several key clinical and basic science investigations including: 1) to test the efficacy of the famesyl transferase inhibitor, Rl15777, in untreated JMML patients, 2) to utilize this phase II window approach to evaluate other molecularly targeted, mechanism-based therapeutics for JMML, and 3) to determine the actual frequency of NFI and RAS gene abnormalities in JMML patients and correlate these results with known clinical prognostic markers to determine if therapeutically relevant, biologically-defined subsets of JMML exist, towards which future mechanism-based therapies can be specifically directed. Thus, the translational experiments proposed in this application are based on our understanding of JMML pathogenesis, and will provide novel data about the pharmacodynamics of targeted therapeutics. Beyond JMML, these studies may uncover agents that inhibit Ras that ultimately prove to be broadly applicable to other myeloid malignancies and to a broad range of human cancers.
描述(由申请人提供):JMML的发病机理已与通过RAS途径失调的GM-CSF生长因子信号转导失调,在该途径中的RAS和NF1基因中鉴定出异常。 这种失调导致JMML细胞在体外表现出对GM-CSF的选择性超敏反应。 JMML 13-钙视黄酸治疗中的新治疗方式之一似乎调节了这种GM-CSF超敏反应。 NCI的CTEP分支最近批准了针对JMML的新的多模式治疗方案。 该方案将通过儿童肿瘤学组进行管理,是II期窗口/III期试验。将在II期窗口中测试使用Farnesyl转移酶抑制剂的实验疗法,然后在III期部分中进行13 cis视黄酸,化学疗法和干细胞移植。 这种类型的试验设计的众多优点之一是,它允许对单个药物在未患有耐药性的未经治疗的JMML患者中的疗效进行严格的评估。 如果一个II期代理的尾巴,则该方案旨在允许替换不同的药物,而不会破坏研究的其余部分。 在III期试验过程中,可以几乎对三种实验试剂进行全面测试。 实验室研究将评估它们是否真正充当基于机制的治疗学。 The principal aims of this application are to utilize the patient resources from this protocol as a conduit for accruing cases to address several key clinical and basic science investigations including: 1) to test the efficacy of the famesyl transferase inhibitor, Rl15777, in untreated JMML patients, 2) to utilize this phase II window approach to evaluate other molecularly targeted, mechanism-based therapeutics for JMML, and 3) to determine the JMML患者中NFI和RAS基因异常的实际频率,并将这些结果与已知的临床预后标记相关,以确定是否存在治疗性相关的JMML的治疗性相关,生物定义的子集存在,可以专门针对未来基于机制的疗法。 因此,本应用程序中提出的翻译实验是基于我们对JMML发病机理的理解,并将提供有关靶向治疗药物的药效学的新数据。除了JMML之外,这些研究可能会揭示抑制RA的药物,这些药物最终被证明广泛适用于其他髓样恶性肿瘤和广泛的人类癌症。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
PETER D. EMANUEL其他文献
PETER D. EMANUEL的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('PETER D. EMANUEL', 18)}}的其他基金
Construction completion of the Cancer Institute's shelled space on floors 9 and 1
癌症研究所 9 楼和 1 楼的外壳空间竣工
- 批准号:
7875313 - 财政年份:2010
- 资助金额:
$ 2.86万 - 项目类别:
相似国自然基金
自然接触对青少年网络问题行为的作用机制及其干预
- 批准号:72374025
- 批准年份:2023
- 资助金额:40 万元
- 项目类别:面上项目
大气污染物对青少年心理健康的影响机制研究
- 批准号:42377437
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
心肺耐力对青少年执行功能影响效应及其特定脑区激活状态的多民族研究
- 批准号:82373595
- 批准年份:2023
- 资助金额:47 万元
- 项目类别:面上项目
中国父母情绪教养行为对青少年非自杀性自伤的影响及其机制
- 批准号:32300894
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
执行技能训练联合动机行为治疗对注意缺陷多动障碍青少年疗效及脑机制
- 批准号:82371557
- 批准年份:2023
- 资助金额:65 万元
- 项目类别:面上项目
相似海外基金
Executive functions in urban Hispanic/Latino youth: exposure to mixture of arsenic and pesticides during childhood
城市西班牙裔/拉丁裔青年的执行功能:童年时期接触砷和农药的混合物
- 批准号:
10751106 - 财政年份:2024
- 资助金额:
$ 2.86万 - 项目类别:
Identification of Prospective Predictors of Alcohol Initiation During Early Adolescence
青春期早期饮酒的前瞻性预测因素的鉴定
- 批准号:
10823917 - 财政年份:2024
- 资助金额:
$ 2.86万 - 项目类别:
HealthyU-Latinx: A Technology-based Tool for addressing Health Literacy in Latinx Secondary Students and their Families
HealthyU-Latinx:一种基于技术的工具,用于提高拉丁裔中学生及其家庭的健康素养
- 批准号:
10699830 - 财政年份:2023
- 资助金额:
$ 2.86万 - 项目类别:
Screening and Brief Intervention for Prescription Stimulant Misuse and Diversion: Refining and Piloting a Curriculum for College Health Providers
针对处方兴奋剂滥用和转移的筛查和简短干预:为大学医疗服务提供者完善和试点课程
- 批准号:
10731122 - 财政年份:2023
- 资助金额:
$ 2.86万 - 项目类别:
Impact of cannabis legalization on prescription drug use and health outcomes in Connecticut
大麻合法化对康涅狄格州处方药使用和健康结果的影响
- 批准号:
10576002 - 财政年份:2023
- 资助金额:
$ 2.86万 - 项目类别: